Therefore, EGFR mutation screening may have a higher impact on the selection of responders to gefitinib treatment among these kinds of Asian patient subset (for example, smokers with adenocarcinoma, and nonsmoking men or women with nonadenocarcinoma). This evidence concerns the gene EGFR and adenocarcinoma.